Health utility book: A systematic review and meta-analysis of health utilities in gastric cancer.

IF 3 3区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Supportive Care in Cancer Pub Date : 2025-10-04 DOI:10.1007/s00520-025-09993-7

Shant Torkom Yeretzian, Brittany Humphries, Meixuan Li, Chiranjeev Sanyal, Gaurav Talwar, Michael Xu, Peijing Yan, Frances Simbulan, Zhiyuan Chen, Pei Wang, Ting Zhou, Veena Manja, Xuejing Jin, Yuan Sun, Preston Tse, Michael J Zoratti, Shitong Xie, Feng Xie

{"title":"Health utility book: A systematic review and meta-analysis of health utilities in gastric cancer.","authors":"Shant Torkom Yeretzian, Brittany Humphries, Meixuan Li, Chiranjeev Sanyal, Gaurav Talwar, Michael Xu, Peijing Yan, Frances Simbulan, Zhiyuan Chen, Pei Wang, Ting Zhou, Veena Manja, Xuejing Jin, Yuan Sun, Preston Tse, Michael J Zoratti, Shitong Xie, Feng Xie","doi":"10.1007/s00520-025-09993-7","DOIUrl":null,"url":null,"abstract":"Purpose: The treatment landscape in gastric cancer has changed drastically over the last 15 years with surgical advancements and the introduction of new therapeutic agents and combinations. Despite the potential for improved survival, these new interventions can impact health-related quality of life (HRQoL). Our objective was to identify and synthesize health utility data for gastric cancer patients as part of the Health Utility Book (HUB) project.Methods: We searched MEDLINE, EMBASE, EconLit, and CINAHL from inception to March 2023 for original studies that reported health utility data for gastric cancer. Records were screened independently and in duplicate by two reviewers. Data on study design, patient characteristics, and health utilities were extracted using a standardized form. A random effects meta-analysis was conducted to synthesize health utilities by cancer stage. Heterogeneity was evaluated using the I2 statistic.Results: 600 health utilities from 3,405 respondents were identified across 19 studies. All studies were published between 2018 and 2022 and most were conducted in Asia (n = 12, 63.2%). The EQ-5D was the most common method of preference elicitation (n = 17, 89.5%), and health utilities ranged from 0.298 (SD 0.088) to 0.920 (SD 0.130). Mean health utilities from random effects models were 0.82 (95% Confidence Interval [CI] 0.76-0.88), 0.76 (95% CI 0.68-0.85), and 0.67 (95% CI 0.46-0.87) for early stage, advanced stage, and metastatic gastric cancer, respectively.Conclusion: This systematic review provides a reference set of health utilities for gastric cancer, which can help understand HRQoL and facilitate the retrieval and selection of health utilities for economic evaluations.","PeriodicalId":22046,"journal":{"name":"Supportive Care in Cancer","volume":"33 10","pages":"907"},"PeriodicalIF":3.0000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Supportive Care in Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00520-025-09993-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: The treatment landscape in gastric cancer has changed drastically over the last 15 years with surgical advancements and the introduction of new therapeutic agents and combinations. Despite the potential for improved survival, these new interventions can impact health-related quality of life (HRQoL). Our objective was to identify and synthesize health utility data for gastric cancer patients as part of the Health Utility Book (HUB) project.

Methods: We searched MEDLINE, EMBASE, EconLit, and CINAHL from inception to March 2023 for original studies that reported health utility data for gastric cancer. Records were screened independently and in duplicate by two reviewers. Data on study design, patient characteristics, and health utilities were extracted using a standardized form. A random effects meta-analysis was conducted to synthesize health utilities by cancer stage. Heterogeneity was evaluated using the I² statistic.

Results: 600 health utilities from 3,405 respondents were identified across 19 studies. All studies were published between 2018 and 2022 and most were conducted in Asia (n = 12, 63.2%). The EQ-5D was the most common method of preference elicitation (n = 17, 89.5%), and health utilities ranged from 0.298 (SD 0.088) to 0.920 (SD 0.130). Mean health utilities from random effects models were 0.82 (95% Confidence Interval [CI] 0.76-0.88), 0.76 (95% CI 0.68-0.85), and 0.67 (95% CI 0.46-0.87) for early stage, advanced stage, and metastatic gastric cancer, respectively.

Conclusion: This systematic review provides a reference set of health utilities for gastric cancer, which can help understand HRQoL and facilitate the retrieval and selection of health utilities for economic evaluations.

查看原文本刊更多论文

健康效用书：对胃癌健康效用的系统回顾和荟萃分析。

目的：在过去的15年里，随着外科手术的进步和新的治疗药物和组合的引入，胃癌的治疗前景发生了巨大的变化。尽管有可能提高生存率，但这些新的干预措施可能会影响与健康相关的生活质量（HRQoL）。我们的目标是识别和综合胃癌患者的健康效用数据，作为健康效用书（HUB）项目的一部分。方法：我们检索MEDLINE、EMBASE、EconLit和CINAHL，从成立到2023年3月，检索报道胃癌健康实用数据的原始研究。记录由两名审稿人独立筛选，一式两份。使用标准化表格提取有关研究设计、患者特征和健康效用的数据。采用随机效应荟萃分析综合癌症分期的健康效用。采用I2统计量评估异质性。结果：在19项研究中，从3,405名受访者中确定了600家医疗机构。所有研究发表于2018年至2022年之间，大多数在亚洲进行（n = 12, 63.2%）。EQ-5D是最常见的偏好激发方法（n = 17, 89.5%），健康效用范围为0.298 （SD 0.088）至0.920 （SD 0.130）。随机效应模型对早期、晚期和转移性胃癌的平均健康效用分别为0.82（95%可信区间[CI] 0.76-0.88）、0.76 （95% CI 0.68-0.85）和0.67 （95% CI 0.46-0.87）。结论：本系统综述为胃癌患者提供了一套健康实用工具参考，有助于了解患者的HRQoL，便于检索和选择健康实用工具进行经济评价。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Supportive Care in Cancer 医学-康复医学

CiteScore

5.70

自引率

9.70%

发文量

751

审稿时长

3 months

期刊介绍： Supportive Care in Cancer provides members of the Multinational Association of Supportive Care in Cancer (MASCC) and all other interested individuals, groups and institutions with the most recent scientific and social information on all aspects of supportive care in cancer patients. It covers primarily medical, technical and surgical topics concerning supportive therapy and care which may supplement or substitute basic cancer treatment at all stages of the disease. Nursing, rehabilitative, psychosocial and spiritual issues of support are also included.